ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

Publications

ASLAN004

Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1
N.T. Redpath, Y. Xu, N.J. Wilson, L.J. Fabri, M. Baca, A.E. Andrews, H. Braley, P. Lu, C. Ireland, R.E. Ernst, A. Woods, G. Forrest, Z. An, D.M. Zaller, W.R. Strohl, C.S. Luo, P.E. Czabotar, T.P.J Garrett, D.J. Hilton, A.D. Nash, J.G. Zhang, N.A. Nicola
Biochem. J. (2013), Note: antibody 10G5-6 is ASLAN004

ASLAN003

ASLAN003, A Potent Dihydroorotate Dehydrogenase Inhibitor For Differentiation Of Acute Myeloid Leukemia
J. Zhou, J.Y. Quah, J.Y. Chooi, S.H. Toh, B. Lin, T.Z. Tan, H. Hosoi, M. Osato, Q. Seet, L. Ooi, B. Lindmark, M. McHale, W.J. Chng

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia
J. Zhou, J.Y. Quah, J.Y. Chooi, S.H. Toh, B. Lin, M. Osato, Q. Seet, L. Ooi, B. Lindmark, M. McHale, W.J. Chng
ASH (2018), Poster number: 4047

Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity
S.B. Ting, C.H. Ng, A. Bajel, W.Y.K. Hwang, H.J. Shih, W.J. Chng, M. McHale, C.Y. Hsieh, H.J. Shih, N. McIntyre, J. Kwek , W.L. Chang, B. Lindmark.
ASH (2018), Poster number: 2676

A phase IIa dose optimization study of ASLAN003 in Acute Myeloid Leukemia (AML)
C.H. Ng, S.B. Ting, W.Y.K. Hwang, A. Bajel, R. Eek, M. McHale, H.-J. Shih, N. McIntyre, J. Kwek , B. Lindmark.
ESMO (2018), Abstract number: 1043TiP

Related Publications
Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.
K.K. Brown, J.B. Spinelli, J.M. Asara, A. Toker.
Cancer Discovery (2017), 7(4), 1-9.

PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition.
Mathur, E. Stratikopoulos, S. Ozturk, N. Steinbach, S. Pegno, S. Schoenfeld, R. Yong, V.V. Murty, J.M. Asara, L.C. Cantley, R. Parsons.
Cancer Discovery (2017), 7(4), 380-390.

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
D.B. Sykes, Y.S. Kfoury, F.E. Mercier, M.J. Wawer, J.M. Law, M.K. Haynes, T.A. Lewis, A. Schajnovitz, E. Jain, D. Lee, H. Meyer, K.A. Pierce, N.J. Tolliday, A. Waller, S.J. Ferrara, A.L. Eheim, D. Stoeckigt, K.L. Maxcy, J.M. Cobert, J. Bachand, B.A. Szekely, S. Mukherjee, L.A. Sklar, J.D. Kotz, C.B. Clish, R.I. Sadreyev, P.A. Clemons, A. Janzer, S.L. Schreiber, D.T. Scadden.
Cell (2016), 167, 1-16.

The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
A.A. Khutornenko, A.A. Dalina, B.V. Chernyak, P.M. Chumakov, A.G. Evstafieva.
Acta Naturae (2014), 6(1), 69-75.

Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway.
A.A. Khutornenko, V.V. Roudko, B.V. Chernyak, A.B. Vartapetian, P.M. Chumakov, A.G. Evstafieva.
PNAS (2010), 107(29), 12828-12833.